Apoiar as comunidades envolvidas na doença de estudos

Lack of continued help for poor families involved in Huntington’s-disease research has sown resentment and mistrust, says Ignacio Muñoz-Sanjuan.

By Ignacio Muñoz-Sanjuan

After decades of research, a genetic therapy for Huntington’s disease is being tested in clinical trials. Sponsored by Swiss pharmaceutical firm Roche and US-based Ionis Pharmaceuticals, this trial targets the gene that causes the disease. If the new treatment works, it could offer a way to halt progression of this genetic disease — an awful neurodegenerative disorder that attacks mainly the brain. Huntington’s is caused by a single gene mutation transmitted in a dominant fashion, so a child has a 50% chance of inheriting the condition if one of their parents carries a single copy of the defective gene. KEEP READING.

FUENTE: Nature Magazine

Deixe um comentário

O seu endereço de e-mail não será publicado.

Posts Relacionados

A Coleta De Dados & Advocacia

Atender Ignacio – uma CRL entrevista

Meet our second disruptor Ignacio Muñoz-Sanjuán. Find out how Ignacio’s work is enabling organizations to develop novel therapies for Huntington’s

Ler Mais "

Deixe uma Resposta